Coordinating Tissue Regeneration through TGF-β Activated Kinase 1 (TAK1) In-activation and Re-activation

Aberrant wound healing presents as inappropriate or insufficient tissue formation. Using a model of musculoskeletal injury, we demonstrate that loss of TGF-β activated kinase 1 (TAK1) signaling reduces inappropriate tissue formation (heterotopic ossification) through reduced cellular differentiation...

Full description

Saved in:
Bibliographic Details
Published in:Stem cells (Dayton, Ohio) Vol. 37; no. 6; pp. 766 - 778
Main Authors: Hsieh, Hsiao Hsin Sung, Agarwal, Shailesh, Cholok, David J., Loder, Shawn J., Kaneko, Kieko, Huber, Amanda, Chung, Michael T., Ranganathan, Kavitha, Habbouche, Joe, Li, John, Butts, Jonathan, Reimer, Jonathan, Kaura, Arminder, Drake, James, Breuler, Christopher, Priest, Caitlin R., Nguyen, Joe, Brownley, Cameron, Peterson, Jonathan, Ozgurel, Serra Ucer, Niknafs, Yashar S., Li, Shuli, Inagaki, Maiko, Scott, Greg, Krebsbach, Paul, Longaker, Michael T., Westover, Kenneth, Gray, Nathanael, Jun-Ninomiya-Tsuji, Mishina, Yuji, Levi, Benjamin
Format: Journal Article
Language:English
Published: 14-03-2019
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aberrant wound healing presents as inappropriate or insufficient tissue formation. Using a model of musculoskeletal injury, we demonstrate that loss of TGF-β activated kinase 1 (TAK1) signaling reduces inappropriate tissue formation (heterotopic ossification) through reduced cellular differentiation. Upon identifying increased proliferation with loss of TAK1 signaling, we considered a regenerative approach to address insufficient tissue production through coordinated inactivation of TAK1 to promote cellular proliferation, followed by re-activation to elicit differentiation and extracellular matrix (ECM) production. While the current regenerative medicine paradigm is centered on the effects of drug treatment (“drug on”), the impact of drug withdrawal (“drug off”) implicit in these regimens are unknown. Because current TAK1 inhibitors are unable to phenocopy genetic Tak1 loss, we introduce the dual-inducible COmbinational Sequential Inversion ENgineering (COSIEN) mouse model. The COSIEN mouse model, which allows us to study the response to targeted drug treatment (“drug on”) and subsequent withdrawal (“drug off”) through genetic modification, was used here to inactivate and re-activate Tak1 with the purpose of augmenting tissue regeneration in a calvarial defect model. Our study reveals the importance of both the “drug on” (Cre-mediated inactivation) and “drug off” (Flp-mediated re-activation) states during regenerative therapy using a mouse model with broad utility to study targeted therapies for disease.
Bibliography:indicates shared first authorship
CONTRIBUTIONS
Study design: HHSH, SA, YM, and BL. Study conduct, data collection, and data analysis: HHSH, SA, DC, SJL, KK, AH, MC, KR, JH, JL, JN, JR, AK, JD, CB, CP, JN, CB, JP, SUO, YN, SL, YM, and BL. Provide critical materials: MI, GS, PK, MTL, KW, NG, JNT, YM, and BL. Drafting manuscript: HHSH, SA, DC, MC, SJL, YM, and BL. Approving final version of manuscript: HHSH, SA, DC, SJL, KK, AH, MC, KR, JH, JL, JB, JR, AK, JD, CB, CP, JN, CB, JP, SUO, YN, SL, MI, GS, PK, MTL, KW, NG, JNT, YM, and BL. HHSH, SA, and BL take responsibility for the integrity of the data analysis.
indicates shared corresponding authorship
ISSN:1066-5099
1549-4918
DOI:10.1002/stem.2991